Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Metformin directly targets the H3K27me3 demethylase KDM6A/UTX

E. Cuyàs, S. Verdura, L. Llorach-Pares, S. Fernández-Arroyo, F. Luciano-Mateo, N. Cabré, J. Stursa, L. Werner, B. Martin-Castillo, B. Viollet, J. Neuzil, J. Joven, A. Nonell-Canals, M. Sanchez-Martinez, JA. Menendez,

. 2018 ; 17 (4) : e12772. [pub] 20180508

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
SAF2016-80639-P Ministerio de Ciencia e Innovación - International
Plan Nacional de I+D+I, Spain - International
2014 SGR229 Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) - International
Departament d'Economia i Coneixement, Catalonia, Spain - International
16-31604A Czech Health Council Foundation - International
CD15/00033 Ministerio de Sanidad y Consumo - International
Fondo de Investigación Sanitaria (FIS), Spain - International
Roche Pharma (Spain) - International
Astellas Pharma (Spain) - International
Armangué family (Girona, Catalonia) to the Metabolism and Cancer Group (Girona Biomedical Research Institute) - International
NV16-31604A MZ0 CEP Register

Metformin, the first drug chosen to be tested in a clinical trial aimed to target the biology of aging per se, has been clinically exploited for decades in the absence of a complete understanding of its therapeutic targets or chemical determinants. We here outline a systematic chemoinformatics approach to computationally predict biomolecular targets of metformin. Using several structure- and ligand-based software tools and reference databases containing 1,300,000 chemical compounds and more than 9,000 binding sites protein cavities, we identified 41 putative metformin targets including several epigenetic modifiers such as the member of the H3K27me3-specific demethylase subfamily, KDM6A/UTX. AlphaScreen and AlphaLISA assays confirmed the ability of metformin to inhibit the demethylation activity of purified KDM6A/UTX enzyme. Structural studies revealed that metformin might occupy the same set of residues involved in H3K27me3 binding and demethylation within the catalytic pocket of KDM6A/UTX. Millimolar metformin augmented global levels of H3K27me3 in cultured cells, including reversion of global loss of H3K27me3 occurring in premature aging syndromes, irrespective of mitochondrial complex I or AMPK. Pharmacological doses of metformin in drinking water or intraperitoneal injection significantly elevated the global levels of H3K27me3 in the hepatic tissue of low-density lipoprotein receptor-deficient mice and in the tumor tissues of highly aggressive breast cancer xenograft-bearing mice. Moreover, nondiabetic breast cancer patients receiving oral metformin in addition to standard therapy presented an elevated level of circulating H3K27me3. Our biocomputational approach coupled to experimental validation reveals that metformin might directly regulate the biological machinery of aging by targeting core chromatin modifiers of the epigenome.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045465
003      
CZ-PrNML
005      
20200113082240.0
007      
ta
008      
200109s2018 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/acel.12772 $2 doi
035    __
$a (PubMed)29740925
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Cuyàs, Elisabet $u ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism & Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain. Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
245    10
$a Metformin directly targets the H3K27me3 demethylase KDM6A/UTX / $c E. Cuyàs, S. Verdura, L. Llorach-Pares, S. Fernández-Arroyo, F. Luciano-Mateo, N. Cabré, J. Stursa, L. Werner, B. Martin-Castillo, B. Viollet, J. Neuzil, J. Joven, A. Nonell-Canals, M. Sanchez-Martinez, JA. Menendez,
520    9_
$a Metformin, the first drug chosen to be tested in a clinical trial aimed to target the biology of aging per se, has been clinically exploited for decades in the absence of a complete understanding of its therapeutic targets or chemical determinants. We here outline a systematic chemoinformatics approach to computationally predict biomolecular targets of metformin. Using several structure- and ligand-based software tools and reference databases containing 1,300,000 chemical compounds and more than 9,000 binding sites protein cavities, we identified 41 putative metformin targets including several epigenetic modifiers such as the member of the H3K27me3-specific demethylase subfamily, KDM6A/UTX. AlphaScreen and AlphaLISA assays confirmed the ability of metformin to inhibit the demethylation activity of purified KDM6A/UTX enzyme. Structural studies revealed that metformin might occupy the same set of residues involved in H3K27me3 binding and demethylation within the catalytic pocket of KDM6A/UTX. Millimolar metformin augmented global levels of H3K27me3 in cultured cells, including reversion of global loss of H3K27me3 occurring in premature aging syndromes, irrespective of mitochondrial complex I or AMPK. Pharmacological doses of metformin in drinking water or intraperitoneal injection significantly elevated the global levels of H3K27me3 in the hepatic tissue of low-density lipoprotein receptor-deficient mice and in the tumor tissues of highly aggressive breast cancer xenograft-bearing mice. Moreover, nondiabetic breast cancer patients receiving oral metformin in addition to standard therapy presented an elevated level of circulating H3K27me3. Our biocomputational approach coupled to experimental validation reveals that metformin might directly regulate the biological machinery of aging by targeting core chromatin modifiers of the epigenome.
650    _2
$a zvířata $7 D000818
650    _2
$a biokatalýza $7 D055162
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a inhibitory enzymů $x chemie $x farmakologie $7 D004791
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a histondemethylasy $x antagonisté a inhibitory $x metabolismus $7 D056466
650    _2
$a lidé $7 D006801
650    _2
$a ligandy $7 D008024
650    _2
$a metformin $x chemie $x farmakologie $7 D008687
650    _2
$a myši $7 D051379
650    _2
$a myši knockoutované $7 D018345
650    _2
$a molekulární modely $7 D008958
650    _2
$a molekulární struktura $7 D015394
650    _2
$a experimentální nádory $x farmakoterapie $x metabolismus $7 D009374
650    _2
$a jaderné proteiny $x antagonisté a inhibitory $x metabolismus $7 D009687
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Verdura, Sara $u ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism & Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain. Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
700    1_
$a Llorach-Pares, Laura $u Mind the Byte, Barcelona, Spain.
700    1_
$a Fernández-Arroyo, Salvador $u Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, IISPV, Rovira i Virgili University, Reus, Spain.
700    1_
$a Luciano-Mateo, Fedra $u Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, IISPV, Rovira i Virgili University, Reus, Spain.
700    1_
$a Cabré, Noemí $u Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, IISPV, Rovira i Virgili University, Reus, Spain.
700    1_
$a Stursa, Jan $u Institute of Chemical Technology, Prague, Czech Republic. Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech Republic.
700    1_
$a Werner, Lukas $u Institute of Chemical Technology, Prague, Czech Republic. Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech Republic.
700    1_
$a Martin-Castillo, Begoña $u Unit of Clinical Research, Catalan Institute of Oncology, Girona, Spain.
700    1_
$a Viollet, Benoit $u INSERM U1016, Institut Cochin, Paris, France. CNRS UMR 8104, Paris, France. Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
700    1_
$a Neuzil, Jiri $u Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech Republic. School of Medical Science, Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia.
700    1_
$a Joven, Jorge $u Unitat de Recerca Biomèdica, Hospital Universitari de Sant Joan, IISPV, Rovira i Virgili University, Reus, Spain.
700    1_
$a Nonell-Canals, Alfons $u Mind the Byte, Barcelona, Spain.
700    1_
$a Sanchez-Martinez, Melchor $u Mind the Byte, Barcelona, Spain.
700    1_
$a Menendez, Javier A $u ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism & Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain. Girona Biomedical Research Institute (IDIBGI), Girona, Spain.
773    0_
$w MED00007638 $t Aging cell $x 1474-9726 $g Roč. 17, č. 4 (2018), s. e12772
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29740925 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113082612 $b ABA008
999    __
$a ok $b bmc $g 1483734 $s 1084138
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 17 $c 4 $d e12772 $e 20180508 $i 1474-9726 $m Aging cell $n Aging cell $x MED00007638
GRA    __
$a SAF2016-80639-P $p Ministerio de Ciencia e Innovación $2 International
GRA    __
$p Plan Nacional de I+D+I, Spain $2 International
GRA    __
$a 2014 SGR229 $p Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) $2 International
GRA    __
$p Departament d'Economia i Coneixement, Catalonia, Spain $2 International
GRA    __
$a 16-31604A $p Czech Health Council Foundation $2 International
GRA    __
$a CD15/00033 $p Ministerio de Sanidad y Consumo $2 International
GRA    __
$p Fondo de Investigación Sanitaria (FIS), Spain $2 International
GRA    __
$p Roche Pharma (Spain) $2 International
GRA    __
$p Astellas Pharma (Spain) $2 International
GRA    __
$p Armangué family (Girona, Catalonia) to the Metabolism and Cancer Group (Girona Biomedical Research Institute) $2 International
GRA    __
$a NV16-31604A $p MZ0
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...